If you don’t like the ECA or other aspects of the landmark P3, then you have other DCVax-L clinical trials to consider.
All clinical data are relevant to the FDA whenever they must make a decision about the safety and efficacy of any drug.
DCVax-L has been studied in placebo trials too if you like internally controlled trials. DCVax-L is currently being studied in combo with Keytruda at UCLA in an internally controlled study supported by Merck and the NIH (NCI).
Don’t miss the two conferences where Northwest Biotherapeutics is scheduled to participate—BNOS in July (the conference starts today!) and CNS in September!